extension until the end of 2021 for the old formula

Since 2017, no other drug has reached the ankle of Levothyrox. Several associations won their case for this extension.

Levothyrox is a drug that treats hypothyroidism. Besides, do you know the different symptoms of the disease?

• Fatigue and a lack of energy;
• chilliness;
• depression;
• weight gain ;
• constipation ;
• a drop in heart rate;
• edema (especially on the face, with puffy eyes);
• muscle aches.

There are plenty of other symptoms, see a doctor if you experience any of them. You will be entitled to Levothyrox. Moreover, a letter was recently distributed by the Ministry of Health. This explains an extension until the end of 2021 for the current formula of Levothyrox. During the first quarter of 2020, nearly 95,000 patients were treated with the formula.

Huge relief for patients

Indeed, this announcement is a huge relief for patients with the disease. Condemning patients on the only drug that works would have been a serious mistake. A poignant argument that was used by various associations. The COVID-19 pandemic was also taken into account in this decision.

A radical change given the words of the Ministry of Health. During a ministerial committee that took place on July 6, senior officials said Euthyrox should be arrested as early as September.

“ANSM has asked the Merck laboratories to make every effort to maintain the Euthyrox specialty in France beyond September 2020. (…) The Merck laboratories have their agreement regarding this request. Therefore, the maintenance of Euthyrox in France will continue in 2021. This extension of Euthyrox distribution will give affected patients additional time to initiate the change of treatment, as soon as possible for a sustainable therapeutic alternative», Explains the Directorate General for Health (DGS)

Euthyrox is basically intended for the Russian market. The old formula is being imported on a temporary basis. We will keep you informed of the next news on the Levothyrox.

–